Congressional Doctors Caucus Urges FDA to Consider Physician Input on Biosimilar Labeling
January 21, 2016
It’s time for clarity about the prescribing information that accompanies biosimilar medications, the U.S. House Doctors Caucus told the FDA in a Dec. 21, 2015 letter. What’s more, signers of the letter argue, the FDA should “solicit and consider” physician viewpoints when crafting the long-anticipated regulatory guidance.
The House Doctors Caucus includes 18 medical providers who also serve in Congress, using their medical expertise to shape health care policy. Rep. Brad Wenstrup (R-Ohio), a caucus member and a physician for more than 25 years, explained that biosimilars offered options for expanding treatment and reducing health care costs – but only if “physicians feel comfortable prescribing them and patients feel safe taking them.” Rep. Wenstrup signed the letter along with 11 other caucus members.